📰 Nasdaq Edit News
Page 7 - Nasdaq Edit News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Nasdaq Edit. Real-time updates on events, politics, business and more.
May 16, 2022
Brokerages predict that Editas Medicine, Inc. (NASDAQ:EDIT – Get Rating) will post earnings of ($0.84) per share for the current fiscal quarter, Zacks Investment Research reports. Five analysts have issued estimates for Editas Medicine’s earnings. The lowest EPS estimate is ($0.93) and the highest is ($0.72). Editas Medicine posted earnings of ($0.81) per share in […]
April 25, 2022
Analysts expect that Editas Medicine, Inc. (NASDAQ:EDIT – Get Rating) will post earnings of ($0.81) per share for the current quarter, according to Zacks. Four analysts have provided estimates for Editas Medicine’s earnings. The lowest EPS estimate is ($0.91) and the highest is ($0.75). Editas Medicine reported earnings of ($0.86) per share during the same […]
April 14, 2022
James C. Mullen to Serve as Executive Chairman CAMBRIDGE, Mass., April 14, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading...
April 11, 2022
Marks the first-ever in vivo delivery of an experimental CRISPR gene editing medicine to a pediatric patient Company on track to complete dosing of...
April 6, 2022
Wall Street analysts expect Editas Medicine, Inc. (NASDAQ:EDIT – Get Rating) to report $4.60 million in sales for the current quarter, according to Zacks. Three analysts have issued estimates for Editas Medicine’s earnings. The highest sales estimate is $5.00 million and the lowest is $3.80 million. Editas Medicine reported sales of $6.50 million in the […]
April 4, 2022
Editas Medicine, Inc. (NASDAQ:EDIT – Get Rating) EVP Bruce Eaton sold 1,258 shares of the company’s stock in a transaction dated Friday, April 1st. The shares were sold at an average price of $19.64, for a total transaction of $24,707.12. The transaction was disclosed in a legal filing with the SEC, which is accessible through […]
March 16, 2022
Editas Medicine, Inc. (NASDAQ:EDIT – Get Rating) has earned a consensus recommendation of “Hold” from the thirteen research firms that are covering the firm, MarketBeat reports. Two analysts have rated the stock with a sell rating, four have given a hold rating and six have given a buy rating to the company. The average 12-month […]
March 8, 2022
Cetera Advisor Networks LLC boosted its position in Editas Medicine, Inc. (NASDAQ:EDIT – Get Rating) by 8.4% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 8,667 shares of the company’s stock after purchasing an additional 671 shares during the period. Cetera Advisor Networks […]
March 3, 2022
CAMBRIDGE, Mass., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, announced today the U.S....
December 13, 2021
Preclinical data demonstrating Editas-engineered AsCas12a multiplexed editing of iPSCs enhances iNK tumor killing ability, supporting promise as a...